CL
Therapeutic Areas
Travere Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FILSPARI (sparsentan) | IgA Nephropathy (IgAN) | Approved |
| Sparsentan | Focal Segmental Glomerulosclerosis (FSGS) | Phase 3 |
| Pegtarviliase (TVT-058) | Classical Homocystinuria (HCU) | Phase 3 |
Leadership Team at Travere Therapeutics
ED
Eric Dube, Ph.D.
President & Chief Executive Officer
CC
Chris Cline, CFA
Chief Financial Officer
AG
Angela Giannantonio
Chief People Officer
PH
Peter Heerma
Chief Commercial Officer
JI
Jula Inrig, M.D.
Chief Medical Officer
ER
Elizabeth Reed, J.D.
Chief Legal Officer & General Counsel
WR
William Rote, Ph.D.
Chief Research Officer
CS
Charlotte Smith
Chief Corporate Affairs Officer
GA
Gary A. Lyons
Chairman of the Board
RD
Roy D. Baynes, M.D., Ph.D.
Director